Evangelische Kliniken Gelsenkirchen

Gelsenkirchen 45879

0 studies enrolling now · 2 studies all time

What they study most

HER2-Positive Primary Breast Cancer, Primary Breast Cancer AR+ve TNBN, Primary Breast Cancer ER+ve, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer — Completed